CAS: 122332-18-7; Mivobulin
该化合物是一种属于微囊抑制剂类别的合成化合物,主要研究其可能用于癌症治疗,因为其能够破坏细胞分裂和细胞内迁移所必需的微囊正常功能.Mivubulin展示了一个类似于其他管状目标物剂的行动机制,导致细胞循环停止,迅速分裂癌症细胞中的吸附.该化合物的特征是它与管状素的具体结合性,它防止微囊聚合,从而抑制消化.在物理特性方面,Mivubulin通常是在室温下的固态,在有机溶剂中可能表现出中等溶性.其药理学特征,包括吸收,分配,新陈代谢和排泄,对于确定其临床环境中的功效和安全性至关重要.持续的研究继续探索其治疗潜力,并优化其配方,以取得更好的临床结果.
- 英文名称Mivobulin
- 中文名称(-)-(S)-N-(5-氨基-2-甲基-3-苯基-l,2-二氢吡啶并[3,4-b]吡嗪-7-基)氨基甲酸乙酯
- IUPAC名称ethyl (S)-(5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamate
- 其它别名Ethyl N-[(9S)-5-Amino-9-Methyl-8-Phenyl-4,7,10-Triazabicyclo[4.4.0] Deca-1,3,5,7-Tetraen-3-Yl]Carbamate; Mivobulin [inn]; Calcium Mitiglinide; Mivobulin; Carbamic Acid, N-[(2S)-5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido[3,4-B]Pyrazin-7-Yl]-, Ethyl Ester; Ethyln-[(2S)-5-Amino-2-Methyl-3-Phenyl-1,2-Dihydropyrido[3,4-B]Pyrazin-7-Yl]Carbamate
- CAS编号122332-18-7
- MFCD编号:MFCD14155952
- FDA UNII编号:96U5LG549X
- 分子式:C17H19N5O2
- 分子量:325.37
- 产品CID: 319934
- 同类组份化合物CAS126268-81-3 (Isethionate)122332-18-7 (free base)
- 产品分类医药中间体 → 吡啶类化合物
物理性质
MSDS等安全信息
上下游产品
-5-nitropyridine-2-carbamateethyl (S)-6-amino-4-(1-methyl-2-oxo-2-phenylethyl)-amino-5-nitropyridine-2-carbamate (1R,2S)-norephedrine ethyl (6-amino-4-chloro-5-nitropyridin-2-yl)carbamate -6-amino-4--5-nitropyridine-2-carbamateethyl -6-amino-4-(2-hydroxy-1-methyl-2-phenylethyl)amino-5-nitropyridine-2-carbamate合成工艺路线路线简述
去甲麻黄碱置于镍 吡啶,Chromium(Vi) Oxide,氢气,三乙胺体系中,用 乙醇,二氯甲烷,溶剂黄146 用作溶剂,化学反应生成(-)-(S)-N-(5-氨基-2-甲基-3-苯基-L,2-二氢吡啶并[3,4-B]吡嗪-7-基)氨基甲酸乙酯
参考文献:New Anticancer Agents: Chiral Isomers Of Ethyl 5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido[3,4-B]Pyrazine-7-Carbamate
标题:New Anticancer Agents: Chiral Isomers Of Ethyl 5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido[3,4-B]Pyrazine-7-Carbamate
摘要:Racemic Ethyl 5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido[3,4-B]Pyrazine-7-Carbamate (1A) Has Shown Antitumor Activity In A Variety Of In Vivo Experiments. The Preparation Of The R And S Isomers Gave Compounds With Significant Differences In Potency In Several Biological Tests.
Doi:10.1021/jm00129A012
海关参考信息
- 2902600000-乙苯
2912110000-甲醛
2915110000-甲酸
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9585890-B2
优先权日:2012-09-26
标题 :Modulators of androgen synthesis
发明人：DILLY SUZANNE; STOLOFF GREGORY; TAYLOR PAUL
权利人:TANGENT REPROFILING LTD
摘要:The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
专利号:US-9808462-B2
优先权日:2012-09-26
标题 :Modulators of androgen synthesis
发明人：DILLY SUZANNE; STOLOFF GREGORY; TAYLOR PAUL
权利人:TANGENT REPROFILING LTD
摘要:The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
专利号:US-2014088120-A1
优先权日:2012-09-26
标题 :Modulators of Androgen Synthesis
专利号:CA-2950800-A1
优先权日:2014-05-09
标 题 :Modulators of androgen synthesis
专利号:US-9585887-B2
优先权日:2012-09-26
标题 :Modulators of androgen synthesis
专利号:US-9375433-B2
优先权日:2012-09-26
标 题 :Modulators of androgen synthesis
网址: http://www.jarytimes.com
电话: 010-58236920 13426038769👤
销售电话:010-58236920 13426038769
邮箱：askmryu@126.com
电话: 010-58236920 13426038769👤
📞北京嘉瑞时代科技有限公司 ⚠️参考联系方式
销售电话:010-58236920 13426038769
邮箱：askmryu@126.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002;20(7-8):948-54. . A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study. Cancer Invest. 2002;20(2):192-8.
15: Barbier P, Peyrot V, Dumortier C, D'Hoore A, Rener GA, Engelborghs Y. Kinetics of association and dissociation of two enantiomers, NSC 613863 (R)-(+) and NSC 613862 (S)-(-) (CI 980), to tubulin. Biochemistry. 1996 Feb 13;35(6):2008-15.
合成参考文献
摘要:Sako, M., Science of Synthesis, (2004) 16, 1283.
📝 需求与反馈
尽可能描述清楚需求与问题信息
